Matinas Biopharma Balance Sheet - Annual (NYSEMKT:MTNB)

Add to My Stocks
$0.41 $0.01 (2.38%) MTNB stock closing price Sep 19, 2018 (Closing)

A thorough fundamental analysis involves using data from Matinas Biopharma balance sheet, apart from other financial statements, to value the business. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Matinas Biopharma stock analysis. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. The balance sheet shows total liabilities of $3.74M and shareholders equity of $10.68M. Matinas Biopharma revenue and Matinas Biopharma operating cash flow are important in understanding the financial capacity of the company.

View latest 10 year balance sheet data to check Matinas Biopharma financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Cash7.46M4.26M3.32M2.69M10.84M--
Marketable Securities-------
Receivables-------
Inventory-------
Raw Materials-------
Work In Progress-------
Finished Goods-------
Notes Receivable-------
Other Current Assets-------
Total Current Assets
7.96M4.56M3.55M2.8M10.92M--
Property Plant & Equipment-------
Accumulated Depreciation-------
Net Property Plant & Equipment
1.56M------
Investment & Advances-------
Other Non-Current Assets-------
Deferred Charges-------
Intangibles1.33M1.33M1.33M----
Deposits & Other Assets3.55M3.55M3.13M----
Total Assets
14.42M9.81M8.4M3.36M11.33M--
Notes Payable-------
Accounts Payable-------
Current Portion Long-Term Debt-------
Current Portion Capital Leases-------
Accrued Expenses-------
Income Taxes Payable-------
Other Current Liabilities-------
Total Current Liabilities
2.22M1.44M1.12M1.11M---
Mortgages-------
Deferred Taxes/Income-1.2M1.2M----
Convertible Debt-------
Long-Term Debt-------
Non-Current Capital Leases-------
Other Long-Term Liabilities-------
Total Liabilities
3.74M2.66M2.33M1.13M---
Minority Interest-------
Preferred Stock5.71M6.08M-----
Common Stock Net-------
Capital Surplus56.23M36.23M29.25M16.27M14.3M--
Retained Earnings-51.27M-35.17M-23.18M-14.05M-3.83M-0.11M-
Treasury Stock-------
Other Liabilities-------
Shareholders Equity10.68M7.14M6.07M2.22M10.47M--
Total Liabilities & Shareholders Equity14.42M9.81M8.4M3.36M11.33M--
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Looking at Matinas Biopharma historical stock prices and the current Matinas Biopharma stock price can tell you how the stock price has moved, whereas the Matinas Biopharma PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: An asset is a resource that a corporation like Matinas Biopharma owns and has monetary significance. MTNB assets grew from $9.81M in 2016 to $14.42M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: The total liabilities of Matinas Biopharma for the year 2017 total to $3.74M. Liabilities for a company like Matinas Biopharma include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Matinas Biopharma Balance Sheet - Key Ratios

Current ratio
6.27
Debt to equity ratio
0.01
Asset turnover ratio
0.03
Receivables turnover
12.22
Price to book ratio
3.19